AMC
CLSD

Asset Management Corp’s Clearside Biomedical CLSD Stock Holding History

Asset Management Corp’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$14.6K Buy
+933
New +$18.1K 0.01% 134

Other funds holding CLSD

CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Asset Management Corp's CLSD Position: Q1 2023 in Review

Asset Management Corp opened a new position in Clearside Biomedical (CLSD) in Q1 2023: 933 shares worth $14.6K. The stake represents 0.01% of the portfolio and ranks #134 among its holdings.

50 funds tracked by Wall St. Rank hold CLSD as of Q1 2023.

  • Asset Management Corp held 933 shares of Clearside Biomedical worth $14.6K as of Q1 2023.
  • Clearside Biomedical was a new Asset Management Corp position in Q1 2023.
  • Clearside Biomedical made up 0.01% of Asset Management Corp's portfolio in Q1 2023, its #134 holding.
  • 50 funds tracked by Wall St. Rank held Clearside Biomedical as of Q1 2023.

Based on Asset Management Corp's 13F filing for Q1 2023, filed 14 Apr 2023.